Form D · Pharmaceuticals

Acta Pharmaceuticals, Inc.

Boston, MA · CIK 0001972861

Offering snapshot reported Apr 22, 2024 · SEC filing

Reported sold
$13.4M
Offering amount: $17.5M
Investors reported
29
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 29, 2023
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$6.7M$13.4MApr 7, 2023: $5,049,912.00Apr 7, 2023Apr 22, 2024: $13,400,781.00Apr 22, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$5,049,912 → $13,400,781
  • Reported investors16 → 29

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 22, 2024Amendment$13,400,781$8,350,869vs Apr 7, 202329SEC filing
Apr 7, 2023Initial$5,049,912No comparison16SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-478258

Source: Form D, filed Apr 22, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
George Alex Director, Executive
Thierry Porte Director
Rudolph Tanzi Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
292 Newbury Street
Boston, MA, 02115